Access
To read this story in full you will need to login or make a payment (see right).
News and Views
Nature Medicine 9, 20 - 22 (2003)
doi:10.1038/nm0103-20
Setting the cytokine trap for autoimmunity
Charles A. Dinarello1
- University of Colorado Health Sciences Center Division of Infectious Diseases
Abstract
Agents that block the action of specific cytokines have changed the lives of many patients with rheumatoid arthritis and other autoimmune disorders. But frequent self-injections or injections by a physician during a clinic visit are required. Now a new class of anti-cytokine that may bypass such problems appears on the horizon (pages 47–52).
Protein-based agents that block the action of cytokines have substantially improved treatment for patients with autoimmune diseases over the last five years. Diseases such as rheumatoid arthritis, psoriasis and Crohn's inflammatory bowel disease are now routinely treated with agents such as neutralizing monoclonal antibodies to tumor necrosis factor (TNF; Remicade, also known as infliximab).
To read this story in full you will need to login or make a payment (see right).
|
MORE ARTICLES LIKE THIS These links to content published by NPG are automatically generated REFERENCE REVIEWS NEWS AND VIEWS RESEARCH |
